Michael E. Tarnoff
Known title: DirectorCIK: 0001603289
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
Transaction History
| ANGO | ▲ Buy | Grant | 11,887 | $0 | 7/15/2026 | View on chart |
| RCEL | ▲ Buy | Grant | 22,214 | — | 1/20/2026 | View on chart |
| RCEL | ▲ Buy | Grant | 26,250 | — | 8/6/2025 | View on chart |
| ANGO | ▲ Buy | Grant | 17,675 | $0 | 7/16/2025 | View on chart |
| ANGO | ▲ Buy | Grant | 20,541 | $0 | 7/17/2024 | View on chart |
| ANGO | ▲ Buy | Grant | 17,041 | $0 | 7/19/2023 | View on chart |
| ANGO | ▲ Buy | Grant | 7,060 | $0 | 7/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ANGO Announces Q1 Fiscal 2027 Results Date
AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.
ANGO Announces Q1 Fiscal 2027 Results Date. AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.